Advance | $8,550,000 | (Feb 6, 2026)
Turnstile | $29,000,000 | (Feb 6, 2026)
Accrual | $75,000,000 | (Feb 6, 2026)
Certified by Founder
Lodge
Carmot Therapeutics, Inc.
start up
United States
- Berkeley
- 26/07/2022
- Series D
- $160,000,000
Carmot Therapeutics, Inc. is a clinical-stage company dedicated to the discovery and development of innovative medicines. Carmot applies a transformative, patented drug discovery approach, Chemotype Evolution to explore novel frontiers of chemistry and biology. Using Chemotype Evolution, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology.
- Industry Biotechnology Research
- Website https://carmot-therapeutics.us/contact-us/
- LinkedIn https://www.linkedin.com/company/carmot-therapeutics-inc/
adaption | $50,000,000 | (Feb 6, 2026)
Cadastral | $9,500,000 | (Feb 6, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Nullify | $12,500,000 | (Feb 6, 2026)
Uplift360 | $8,724,008 | (Feb 6, 2026)
Fundamental | $255,000,000 | (Feb 6, 2026)
Duna | $35,365,500 | (Feb 6, 2026)
Flock AI | $6,000,000 | (Feb 6, 2026)